pd168393 has been researched along with pd 153035 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, R; Discafani, C; Floyd, MB; Greenberger, LM; Gruber, BC; Hallett, WA; Johnson, BD; Mamuya, N; Nilakantan, R; Overbeek, E; Rabindran, SK; Reich, MF; Rosfjord, EC; Shen, R; Shi, X; Tsou, HR; Wang, YF; Wissner, A; Ye, F | 1 |
| Antonello, A; Bolognesi, ML; Cavalli, A; Hrelia, P; Melchiorre, C; Morroni, F; Rosini, M; Tarozzi, A | 1 |
2 other study(ies) available for pd168393 and pd 153035
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epi
Topics: Administration, Oral; Aminoquinolines; Aniline Compounds; Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; ErbB Receptors; Glutathione; Humans; Mice; Models, Molecular; Organic Chemicals; Phosphorylation; Receptor, ErbB-2; Structure-Activity Relationship; Substrate Specificity; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Quinazolines | 2006 |